ข่าวประชาสัมพันธ์astrazeneca | newswit
AstraZeneca's long-acting antibody (LAAB) combination granted conditional marketing approval for the treatment of COVID-19 in Thailand – This approval is in addition to the conditional marketing approval granted to LAAB by Thailand's Food and Drug Administration in June 2022, for preventing COVID-19 in a broad population of adults and adolescents, regardless of vaccination status. AstraZeneca finalised an agreement in July
Clinical trials in Russia and Azerbaijan demonstrated safety of AstraZeneca and Sputnik Light vaccines combination – According to the interim results of the trials, involving 100 volunteers in Russia and 100 volunteers in Azerbaijan, the vaccines combination demonstrated an acceptable safety profile, which is consistent with the results of previous AstraZeneca vaccine, Sputnik V and Sputnik Lite vaccines clinical
BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca's portfolio – - Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca's portfolio in Q1 2021BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target
AstraZeneca discloses the making and quality assuring of COVID-19 vaccine manufactured in Thailand – AstraZeneca today reveals manufactured by its production partner in Thailand Siam Bioscience who has been recognised by WHO and is capable of manufacturing COVID-19 vaccine of global quality standard.James Teague, Country President, AstraZeneca (Thailand) Ltd.AstraZeneca is committed to making the vaccine available as soon
